These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 38263684)

  • 1. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
    Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
    Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.
    Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S
    Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.
    Sergi CM
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performances of Fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction-associated steatotic liver disease in Asian primary care clinics.
    Park H; Kim M; Kim HL; Cho S; Yoon EL; Jun DW
    Hepatol Res; 2024 Nov; 54(11):1027-1034. PubMed ID: 38703383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.
    Younossi ZM; Golabi P; Price JK; Owrangi S; Gundu-Rao N; Satchi R; Paik JM
    Clin Gastroenterol Hepatol; 2024 Oct; 22(10):1999-2010.e8. PubMed ID: 38521116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
    Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From NAFLD to MASLD: When metabolic comorbidity matters.
    Hong S; Sun L; Hao Y; Li P; Zhou Y; Liang X; Hu J; Wei H
    Ann Hepatol; 2024; 29(2):101281. PubMed ID: 38135250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
    Suzuki K; Tamaki N; Kurosaki M; Takahashi Y; Yamazaki Y; Uchihara N; Tanaka Y; Miyamoto H; Yamada M; Keitoku T; Okada R; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Izumi N
    Hepatol Res; 2024 Jun; 54(6):600-605. PubMed ID: 38234088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
    Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
    Curr Obes Rep; 2024 Sep; 13(3):510-531. PubMed ID: 38809396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.
    Ishiba H; Sumida Y; Kamada Y; Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Takahashi H; Ueda S; Aishima S; Nakajima A; Okanoue T;
    J Gastroenterol Hepatol; 2023 Jun; 38(6):896-904. PubMed ID: 36797989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
    Targher G; Byrne CD; Tilg H
    Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study.
    Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Yamamura S; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Kawada N; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):370-379. PubMed ID: 35051649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan.
    Tsutsumi T; Kawaguchi T; Fujii H; Kamada Y; Takahashi H; Kawanaka M; Sumida Y; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Morishita A; Munekage K; Kawata K; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Nakajima A; Okanoue T
    Aliment Pharmacol Ther; 2024 Jun; 59(12):1559-1570. PubMed ID: 38651312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
    Canivet CM; Faure S
    Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
    Takahashi Y; Dungubat E; Kusano H; Fukusato T
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.